- Home
- PGC vs ABUS Comparison
PGC vs ABUS Comparison
Compare PGC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGC
- ABUS
- Stock Information
- Founded
- PGC 1921
- ABUS 2005
- Country
- PGC United States
- ABUS United States
- Employees
- PGC N/A
- ABUS N/A
- Industry
- PGC Commercial Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- PGC Finance
- ABUS Health Care
- Exchange
- PGC Nasdaq
- ABUS Nasdaq
- Market Cap
- PGC 540.4M
- ABUS 592.8M
- IPO Year
- PGC N/A
- ABUS N/A
- Fundamental
- Price
- PGC $26.09
- ABUS $3.15
- Analyst Decision
- PGC Strong Buy
- ABUS Strong Buy
- Analyst Count
- PGC 2
- ABUS 4
- Target Price
- PGC $41.50
- ABUS $5.50
- AVG Volume (30 Days)
- PGC 127.2K
- ABUS 1.3M
- Earning Date
- PGC 04-29-2025
- ABUS 05-01-2025
- Dividend Yield
- PGC 0.77%
- ABUS N/A
- EPS Growth
- PGC N/A
- ABUS N/A
- EPS
- PGC 1.85
- ABUS N/A
- Revenue
- PGC $220,392,000.00
- ABUS $6,171,000.00
- Revenue This Year
- PGC $26.94
- ABUS $14.57
- Revenue Next Year
- PGC $15.50
- ABUS $15.84
- P/E Ratio
- PGC $14.10
- ABUS N/A
- Revenue Growth
- PGC 2.25
- ABUS N/A
- 52 Week Low
- PGC $20.30
- ABUS $2.63
- 52 Week High
- PGC $37.88
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- PGC 41.05
- ABUS 46.31
- Support Level
- PGC $23.96
- ABUS $2.71
- Resistance Level
- PGC $27.17
- ABUS $3.34
- Average True Range (ATR)
- PGC 1.40
- ABUS 0.22
- MACD
- PGC 0.05
- ABUS -0.01
- Stochastic Oscillator
- PGC 37.90
- ABUS 48.89
About PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Peapack Private Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and internet banking services. Peapack Private includes asset management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.